n-MYC Amplification
Notes
**Note 1:** This SSDI is effective for diagnosis years 2024+
* For cases diagnosed 2018-2023, leave this SSDI blank
**Note 2:** n-MYC Amplification is a gene that normally regulates cell growth. Studies have shown that n-MYC amplification is an indicator of poor prognosis and increased risk of unfavorable outcomes in patients with neuroblastoma.
* Primary sources of information: molecular pathology report (may be addendum to original pathology report), CAP Protocol
**Note 3:** Physician statement of n-MYC can be used to code this data item when no other information is available.
Metadata
SSDI
| Code |
Description |
| 0 |
Not amplified/negative |
| 1 |
Amplified/positive |
| 2 |
Gain |
| 7 |
Test ordered, results not in chart |
| 8 |
Not applicable: Information not collected for this case
(If this information is required by your standard setter, use of code 8 may result in an edit error) |
| 9 |
Not documented in medical record
Cannot be determined by pathologist
Not applicable (secondary to previous chemotherapy)
n-MYC not assessed or unknown if assessed |
| <BLANK> |
N/A - Diagnosis year is prior to 2024 |
(1) American Society of Clinical Oncology © 2009, The International Neuroblastoma Risk Group (INRG) Classification System: AN INRG Task Force Report; published by American Society of Clinical Oncology, 2009
